182 related articles for article (PubMed ID: 24926857)
1. Apoptotic death of prostate cancer cells by a gonadotropin-releasing hormone-II antagonist.
Park S; Han JM; Cheon J; Hwang JI; Seong JY
PLoS One; 2014; 9(6):e99723. PubMed ID: 24926857
[TBL] [Abstract][Full Text] [Related]
2. A gonadotropin-releasing hormone-II antagonist induces autophagy of prostate cancer cells.
Kim DK; Yang JS; Maiti K; Hwang JI; Kim K; Seen D; Ahn Y; Lee C; Kang BC; Kwon HB; Cheon J; Seong JY
Cancer Res; 2009 Feb; 69(3):923-31. PubMed ID: 19176390
[TBL] [Abstract][Full Text] [Related]
3. Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo.
Gründker C; Föst C; Fister S; Nolte N; Günthert AR; Emons G
Breast Cancer Res; 2010; 12(4):R49. PubMed ID: 20630060
[TBL] [Abstract][Full Text] [Related]
4. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
Jungwirth A; Galvan G; Pinski J; Halmos G; Szepeshazi K; Cai RZ; Groot K; Schally AV
Prostate; 1997 Aug; 32(3):164-72. PubMed ID: 9254895
[TBL] [Abstract][Full Text] [Related]
5. Gonadotropin-releasing hormone induces apoptosis of prostate cancer cells: role of c-Jun NH2-terminal kinase, protein kinase B, and extracellular signal-regulated kinase pathways.
Kraus S; Levy G; Hanoch T; Naor Z; Seger R
Cancer Res; 2004 Aug; 64(16):5736-44. PubMed ID: 15313914
[TBL] [Abstract][Full Text] [Related]
6. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
[TBL] [Abstract][Full Text] [Related]
7. Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors.
Festuccia C; Dondi D; Piccolella M; Locatelli A; Gravina GL; Tombolini V; Motta M
Prostate; 2010 Sep; 70(12):1340-9. PubMed ID: 20623634
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of gonadotropin-releasing hormone (GnRH)-I and GnRH-II on prostate cancer cell signaling and death.
Maiti K; Oh DY; Moon JS; Acharjee S; Li JH; Bai DG; Park HS; Lee K; Lee YC; Jung NC; Kim K; Vaudry H; Kwon HB; Seong JY
J Clin Endocrinol Metab; 2005 Jul; 90(7):4287-98. PubMed ID: 15870130
[TBL] [Abstract][Full Text] [Related]
9. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors.
Lamharzi N; Schally AV; Koppán M
Regul Pept; 1998 Oct; 77(1-3):185-92. PubMed ID: 9809814
[TBL] [Abstract][Full Text] [Related]
10. Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer.
Kittai AS; Blank J; Graff JN
Oncology (Williston Park); 2018 Dec; 32(12):599-602, 604-6. PubMed ID: 30632129
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.
Jungwirth A; Pinski J; Galvan G; Halmos G; Szepeshazi K; Cai RZ; Groot K; Vadillo-Buenfil M; Schally AV
Eur J Cancer; 1997 Jun; 33(7):1141-8. PubMed ID: 9376196
[TBL] [Abstract][Full Text] [Related]
12. Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas.
Clementi M; Sánchez C; Benitez DA; Contreras HR; Huidobro C; Cabezas J; Acevedo C; Castellón EA
Prostate; 2009 Jul; 69(10):1025-33. PubMed ID: 19301301
[TBL] [Abstract][Full Text] [Related]
13. Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo.
Fister S; Günthert AR; Emons G; Gründker C
Cancer Res; 2007 Feb; 67(4):1750-6. PubMed ID: 17308117
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin-releasing hormone in apoptosis of prostate cancer cells.
Kraus S; Naor Z; Seger R
Cancer Lett; 2006 Mar; 234(2):109-23. PubMed ID: 16546667
[TBL] [Abstract][Full Text] [Related]
15. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
Stangelberger A; Schally AV; Zarandi M; Heinrich E; Groot K; Havt A; Kanashiro CA; Varga JL; Halmos G
Prostate; 2007 Sep; 67(12):1339-53. PubMed ID: 17624923
[TBL] [Abstract][Full Text] [Related]
16. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
Steinberg M
Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
[TBL] [Abstract][Full Text] [Related]
17. Increased Intracellular Reactive Oxygen Species Mediates the Anti-Cancer Effects of WZ35 via Activating Mitochondrial Apoptosis Pathway in Prostate Cancer Cells.
Chen M; Zhou B; Zhong P; Rajamanickam V; Dai X; Karvannan K; Zhou H; Zhang X; Liang G
Prostate; 2017 Apr; 77(5):489-504. PubMed ID: 27990666
[TBL] [Abstract][Full Text] [Related]
18. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.
Mimeault M; Johansson SL; Vankatraman G; Moore E; Henichart JP; Depreux P; Lin MF; Batra SK
Mol Cancer Ther; 2007 Mar; 6(3):967-78. PubMed ID: 17363490
[TBL] [Abstract][Full Text] [Related]
19. Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species.
Singh SV; Srivastava SK; Choi S; Lew KL; Antosiewicz J; Xiao D; Zeng Y; Watkins SC; Johnson CS; Trump DL; Lee YJ; Xiao H; Herman-Antosiewicz A
J Biol Chem; 2005 May; 280(20):19911-24. PubMed ID: 15764812
[TBL] [Abstract][Full Text] [Related]
20. Degarelix acetate for the treatment of prostate cancer.
Klotz L
Drugs Today (Barc); 2009 Oct; 45(10):725-30. PubMed ID: 20069136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
